// App-Quantinova.ai

Su1889 : LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR Crohn's DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH TWO YEARS

Researchers

Presenter

  • Paul Rutgeerts

Principal Investigators

  • Christopher Gasink

  • Jean Frederic Colombel

  • Brian G. Feagan

  • Douglas Jacobstein

  • Long-Long Gao

  • Jewel Johanns

  • Bruce E. Sands

  • Stephen B. Hanauer

  • Stephan R. Targan

  • Subrata Ghosh

  • Willem J. de Villiers

Medical Centers

  • University of Stellenbosch, Stellenbosch, South Africa

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

  • UC Davis, Davis, California, United States

  • University Hospital Gasthuisberg, Leuven, Belgium

  • University of Birmingham, Birmingham, United Kingdom

  • Cedars Sinai Medical Center, Los Angeles, California, United States

  • Western Univeristy, London, ON, Canada

Locations

  • Canada

  • United Kingdom

  • United States

  • Belgium

  • South Africa

Companies

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved